ニュース

Shares of biotech company Regeneron (NASDAQ:REGN) fell 10.5% in the afternoon session after its experimental cancer treatment failed to meet the main goal in a late-stage study for patients with a type of advanced skin cancer.

PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

Merck (NYSE:MRK) reported positive global Phase 3 results from the TroFuse-005 trial of its antibody-drug conjugate sacituzumab tirumotecan in advanced or recurrent endometrial cancer. The study showed statistically significant improvement in both overall survival and progression-free survival, a first for an antibody-drug conjugate in this setting. The data could support major regulatory filings and introduce a new treatment option in an area with meaningful unmet medical need. For...

REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.

Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.

MRK's investigational TROP2-directed ADC, sac-TMT, achieves key survival goals in a phase III endometrial cancer study.

Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including...

Futures fell as AI leaders Micron, Sandisk and more keep sliding. Home Depot beat views while Google I/O kicks off.

Merck’s analyst fair value estimate has shifted from US$124.88 to US$129.74 per share, providing an updated reference point for where some on the Street think the stock should trade. That change comes alongside recent research on the Terns deal, oncology pipeline updates, and fresh coverage initiations. Together, these developments help frame how analysts are weighing growth potential against execution and competitive risks. As you read on, you will see what is driving this evolving story and...

Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.

REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.

Shares of Regeneron Pharmaceuticals are down about 11%, dragging the Nasdaq composite, after the company’s experimental melanoma drug failed a pivotal clinical trial. The company said that its drug fianlimab, when combined with an approved cancer drug, didn't keep patients’ disease from worsening significantly longer than Merck’s Keytruda.

Regeneron Pharmaceuticals stock crashed Monday after its experimental melanoma treatment failed in Phase 3 testing.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely watched clinical trial of the year delivered a statistical miss that has prompted a wave of analyst downgrades. The company disclosed on Friday that its phase 3 trial of...

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.

A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.

Shares tumbled after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Merck (NYSE:MRK) plans to present more than 100 oncology abstracts at the 2026 ASCO Annual Meeting. The company will share five year outcomes from pivotal trials of KEYTRUDA combinations in melanoma and triple negative breast cancer. Merck will also highlight data on next generation antibody drug conjugates and individualized neoantigen therapies. For investors following NYSE:MRK, this ASCO 2026 update is at the center of Merck's core oncology focus. KEYTRUDA is a key part of its cancer...

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

The new solar farms boost Matrix’s Spanish portfolio, supporting grid reliability and long-term clean power supply.

Insightful Moves in the First Quarter of 2026

By Twesha Dikshit, Avinash P and Johann M Cherian May 13 (Reuters) - European shares ended higher on Wednesday, led by gains in mining stocks, though caution lingered as investors weighed the economic

Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai